Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Sucampo Pharmaceuticals, Inc. (SCMP)
|
Add to portfolio |
|
|
|
| Price: |
$18.00
| | Metrics |
| OS: |
46.5
|
M
| |
-373
|
% ROE
|
| Market cap: |
$836
|
M
| |
122
|
% ROIC
|
|
Net cash:
|
$75
|
M
| |
$1.62
|
per share
|
|
EV:
|
$761
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$113
|
M
| |
6.7
|
x EV/EBITDA
|
|
EBIT
|
$83.6
|
M
| |
9.1
|
x EV/EBIT
|
| EPS |
($3.27)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 |
| Revenues | 230.1 | 153.2 | 115.5 | 89.6 | 81.5 | 54.8 | 61.9 | 67.4 |
| Revenue growth | 50.2% | 32.7% | 28.9% | 9.9% | 48.8% | -11.5% | -8.1% | -39.9% |
| Cost of goods sold | 76.0 | 36.7 | 16.3 | 12.4 | 3.0 | 72.5 | 0.0 | 0.0 |
| Gross profit | 154.1 | 116.4 | 99.2 | 77.2 | 78.5 | -17.7 | 61.9 | 67.4 |
| Gross margin | 67.0% | 76.0% | 85.9% | 86.2% | 96.3% | -32.3% | 100.0% | 100.0% |
| Sales and marketing | 2.5 | 2.8 | 14.5 | 21.1 | 18.7 | 8.8 | 10.2 | 10.0 |
| Research and development | 46.6 | 33.6 | 20.6 | 21.5 | 21.3 | 33.5 | 24.0 | 32.9 |
| General and administrative | 43.8 | 35.5 | 31.2 | 25.4 | 30.2 | 41.3 | 27.9 | 15.0 |
| EBITA | 86.8 | 48.2 | 33.5 | 10.2 | 8.3 | -17.7 | 0.2 | 9.4 |
| EBITA margin | 37.7% | 31.5% | 29.0% | 11.4% | 10.2% | -32.3% | 0.3% | 14.0% |
| Amortization of intangibles | 25.7 | 3.8 | 0.6 | 1.0 | | | 0.3 | |
| EBIT | 61.2 | 44.5 | 32.9 | 9.2 | 8.3 | -17.7 | -0.2 | 9.4 |
| EBIT margin | 26.6% | 29.0% | 28.5% | 10.3% | 10.2% | -32.3% | -0.2% | 14.0% |
| Pre-tax income | 14.4 | 43.7 | 27.1 | 10.9 | 8.0 | -21.9 | -3.3 | 9.9 |
| Income taxes | -4.1 | 10.3 | 14.0 | 3.9 | 2.9 | -4.6 | -0.6 | 5.1 |
| Tax rate | | 23.6% | 51.6% | 35.9% | 36.6% | 21.0% | 17.0% | 51.6% |
| Net income | 18.5 | 33.4 | 13.1 | 7.0 | 5.1 | -17.3 | -2.8 | 4.8 |
| Net margin | 8.0% | 21.8% | 11.4% | 7.8% | 6.2% | -31.6% | -4.5% | 7.1% |
| |
| Diluted EPS | $0.42 | $0.73 | $0.29 | $0.16 | $0.12 | ($0.41) | ($0.07) | $0.11 |
| Shares outstanding (diluted) | 43.7 | 45.7 | 44.5 | 42.5 | 41.8 | 41.8 | 41.8 | 41.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|